Vitamin D Supplementation for Nonspecific Musculoskeletal Pain in Non-Western Immigrants: A Randomized Controlled Trial

Ferdinand Schreuder, MD
Roos M. D. Bernsen, PhD
Johannes C. van der Wouden, PhD
1Department of General Practice, Erasmus MC, Rotterdam, The Netherlands
2Department of Community Medicine, United Arab Emirates University, United Arab Emirates

ABSTRACT
PURPOSE Many non-Western immigrants report musculoskeletal pains that are hard to treat. We studied the effect of high-dose vitamin D₃ on nonspecific persistent musculoskeletal complaints in vitamin D–deficient non-Western immigrants and assessed correlation of pain patterns with benefit.

METHODS We conducted a semi-crossover randomized controlled trial between February 2008 and February 2010 in primary care in 84 non-Western immigrants visiting their general practitioner for nonspecific musculoskeletal pain. At baseline, patients were randomized to placebo or vitamin D (150,000 IU vitamin D₃ orally); at week 6, patients in the original vitamin D group were randomized a second time to receive vitamin D (again) or to switch to placebo, whereas patients in the original placebo group were all switched to vitamin D. The main outcome was self-assessed change in pain after the first 6 weeks.

RESULTS Patients in the vitamin D group were significantly more likely than their counterparts in the placebo group to report pain relief 6 weeks after treatment (34.9% vs 19.5%, \(P = .04\)). The former were also more likely to report an improved ability to walk stairs (21.0% vs 8.4%, \(P = .008\)). Pain pattern was not correlated with the success of treatment. In a nonsignificant trend, patients receiving vitamin D over 12 weeks were more likely to have an improvement than patients receiving it over 6 weeks.

CONCLUSIONS There is a small positive effect 6 weeks after high-dose vitamin D₃ on persistent nonspecific musculoskeletal pain. Future research should focus on longer follow-up, higher supplementation doses, and mental health.

Ann Fam Med 2012;10:547-555. doi:10.1370/afm.1402.

INTRODUCTION
Many studies report a beneficial effect of vitamin D supplementation on musculoskeletal diseases or complaints, they include not only well-described case reports, but also large intervention studies. Their findings seem to be in line with several cross-sectional studies that have identified a relationship between low serum vitamin D levels and musculoskeletal complaints and muscle weakness. It is not clear whether the pain associated with low vitamin D levels is mainly proximal (as in the case of osteomalacia), is confined to the low back or legs, or is widespread, Other studies have not found any association with pain.

The discovery of vitamin D receptors in muscle cells prompted investigators to look for a muscle analog of osteomalacia. Because vitamin D supplementation may enhance muscle strength, supplementation could also be an easy and inexpensive way to manage nonspecific musculoskeletal pain. This intervention would be of special interest for non-Western immigrants in western Europe, who are prone to vitamin D deficiency and also more often have musculoskeletal problems than white people.
Several nonblinded studies and case reports have documented relief of nonspecific musculoskeletal pain after supplementation with various doses and forms of vitamin D. Gloth et al\(^1\) reported reduced pain 1 week after administration of 50,000 IU vitamin D\(_3\) in 3 elderly patients. Investigators in the Netherlands have described resolution of long-standing pain 6 weeks after administration of 1,200 IU vitamin D\(_3\) daily in 3 Turkish women\(^2\) as well as in 3 girls after several weeks to months of treatment with 2,000 to 3,000 IU vitamin D daily.\(^3\) Eleven severely deficient asylum-seeking women had relief of long-standing pain 4 to 13 weeks after a single dose of 300,000 IU vitamin D given intramuscularly.\(^4\) Seventy vitamin D–deficient women in the Arab United Emirates recovered 4 weeks after injection of 600,000 IU vitamin D\(_3\) or 8 weeks after the start of oral supplementation with 50,000 IU/wk.\(^5\)

In a recent Cochrane systematic review, however, Straube et al\(^6\) did not find evidence for a positive effect of vitamin D therapy and concluded that randomized controlled trials (RCT) are needed to shed light on this issue. After this review, 2 RCTs were published. One trial did not find a pain-relieving effect of vitamin D\(_3\) (800 IU/d or 2 treatments with 10,000 IU) at 6 months in vitamin D–deficient non-Western immigrants aged 18 to 65 years, the majority of whom had fibromyalgia;\(^7\) however, this trial was not designed to evaluate the pain-modifying effect of vitamin D. The other trial was done in elderly Turkish patients from a rheumatology clinic (patients with fibromyalgia were excluded) and found no differences in pain as assessed with a visual analogue scale 4 weeks after administration of 300,000 IU vitamin D (orally or intramuscularly) vs placebo.\(^8\) We aimed to assess the effect of high-dose vitamin D supplementation on nonspecific musculoskeletal symptoms in non-Western vitamin D–deficient immigrants.

### METHODS

#### Study Area, Population, and Design

This semi-crossover randomized controlled trial was conducted between February 2008 and February 2010 in 10 general practices in Delft, The Netherlands, among non-Western immigrants and their offspring, mainly born in the Middle East, Turkey, northern Africa, and Somalia, aged 18 to 60 years, who visited their doctor for frequent, recurrent musculoskeletal pain or pain lasting more than 3 months without an obvious cause (eg, trauma, arthritis, or sciatica). They were tested for vitamin D deficiency, which we defined arbitrarily as a level of 25-hydroxyvitamin D (25-OH-D) of less than 50 nmol/L. Patients who were deficient and met inclusion and exclusion criteria (Table 1) were invited to participate in the study by interpreters who were trained at introducing the study and explaining the questionnaires. Medical care was continued as usual and could include advice and prescription of physiotherapy or medication, but not supplementation with vitamin D. The study was approved by the Medical Ethical Board South West Holland and registered in the international trial register (ISRCTN54027991).

At baseline, 2 independent pharmacists unaware of patients’ treatment allocation dispensed either oral vitamin D (150,000 IU vitamin D\(_3\) in 7.5 mL oil; Viganol, Merck) or oral placebo (7.5 mL oil having same appearance and taste). Bottles were numbered according to a computer-generated randomization list. At week 6, a second randomization was done for patients who had received vitamin D at baseline, but all patients who had received placebo at baseline now received vitamin D. Patients, general practitioners, and interviewers were blinded during the whole trial period. This randomization procedure resulted in 3 groups: one given vitamin D at both baseline and 6 weeks, a second given vitamin D at baseline followed by placebo at 6 weeks, and a third given placebo at baseline and vitamin D at 6 weeks. We chose this design to ensure that all patients received at least some supplementation, to be able to compare at 12 weeks a repeated dose with a single dose; to assess a possible delayed effect of vitamin D supplementation by comparing the vitamin D–placebo group and the placebo–vitamin D group, and to permit comparisons for individual patients of the response to a single dose at 6 weeks with a single dose at 12 weeks.

The interpreters conducted interviews at baseline and at week 6 and week 12. At all time points, patients rated their pain levels in 4 areas of the body on questionnaires using a visual analogue scale (VAS; range, 0-100) and localized pain by marking a mannequin. Use of pain-relieving drugs and physiotherapy were also assessed.

### Table 1. Inclusion and Exclusion Criteria

| Inclusion criteria                                                                                      | Exclusion criteria                                                                                      |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Non-Western immigrant (≥1 parent born in a non-Western country)                                       | Use of vitamin D in the last 4 months                                                                  |
| Aged 18-60 y                                                                                            | Use of statins, cyclosporins, or oral steroids                                                          |
| 25-Hydroxyvitamin D level <50 nmol/L                                                                  | Hypercalcaemia (calcium level >2.55 mmol/L)                                                             |
| Chronic recurrent musculoskeletal pain (>3 episodes of >1 month pain in 2 years) or long-standing pain (>3 months) | sarcoidosis, tuberculosis                                                                                |
| Non-specific pain (no obvious cause such as arthritis, lumbar disc herniation, trauma; patients with fibromyalgia, depression, and low back pain could be included) | Creatinine level >150 mmol/L                                                                            |

*Abbreviations: VAS, visual analogue scale; RCT, randomized controlled trial.*
At both week 6 and week 12, patients were asked about improvement or deterioration (compared with baseline) of their pain on a 5-point Likert scale and about adverse effects. We also assessed self-reported improvement in ability to walk stairs at week 6 and week 12.

At baseline and at week 12, we measured levels of 25-OH-D in serum by radioimmunoassay (Diasorin by SSDZ, Delft). The interassay coefficient of variation was less than 13%. At the end of the study, general practitioners were asked to report any adverse effects and any specific diagnoses (eg, arthritis, sciatica, trauma) made. Patients in whom a specific diagnosis had been made were excluded from analyses.

The trial’s primary outcome was self-reported change in pain after the first 6 weeks of treatment on a 5-point Likert scale. Prespecified secondary outcomes were change in pain at week 12 (Likert scale), self-reported change in ability to walk stairs at week 6 and week 12 (also Likert scales), and VAS scores measuring pain in the neck/shoulders, low back, arms, and legs/joints, and measuring ability to walk stairs.

**Sample Size Calculation**

In calculations, we assumed a significance level of 5%, a power of 80%, and an improvement in 10% of the patients who received placebo at baseline and in 40% of the patients who received vitamin D at baseline. A sample size of 76 patients (38 in each group) would be sufficient to detect this difference. This estimate is conservative because it is based on a dichotomous outcome (improved vs not improved), whereas the actual outcome variable is an ordinal variable with 5 levels.

**Definitions**

We defined treatment success as any improvement in reported pain (either “much less pain” or “less pain”) after the first 6 weeks of treatment. Joint pain was pain in joints only, including pain in the upper arm at the side of a painful shoulder. Proximal pain was pain in the proximal legs and arms, both left and right (lower axial pain could replace pain in proximal legs, and upper axial pain was considered equivalent to pain in the proximal arms). Widespread pain was axial pain plus pain on both sides of the body affecting at least 1 arm or leg.† These 3 subgroups based on pain pattern may overlap.

**Statistical Analysis**

For our primary outcome, we tested the difference at 6 weeks between the 2 groups of patients who received placebo or vitamin D at baseline with the Pearson χ² test for trends. To adhere as much as possible to the intention-to-treat principle, we imputed only the primary variable (Likert scale), by assessing the association between VAS and Likert scale for patients who had both variables available. We used this association to impute the Likert scale for those with missing Likert scale data. This strategy (use of the association between the incomplete variable with ≥1 complete variables) is a common approach for imputing missing values and was used for the Likert scale pain (4 patients) and the Likert scale ability to walk stairs (5 patients).

For self-reported change in ability to climb stairs at 6 weeks, the analysis was similar to the one used for the primary outcome.

To explore whether any difference in effect of vitamin D and placebo might be explained by other interventions, we tested the difference in use of physiotherapy and medication between the 2 groups at 6 weeks (with the Pearson χ² test and Mann-Whitney U test, respectively).

We evaluated 3 VAS outcomes: (1) average VAS (of pain scores for pain in neck and shoulders, low back, arms and legs, and joints), (2) maximum VAS (of these 4 pain scores), and (3) VAS disability in climbing stairs. The absolute difference in improvement between baseline and week 6 for these outcomes between the 2 groups given placebo and vitamin D at baseline was tested with linear regression analysis using the respective baseline VAS score as a covariate.

**Determinants of Treatment Success**

To explore determinants of treatment success, we calculated percentages of patients having success in subgroups based on age, sex, season of enrollment, baseline pain characteristics, baseline VAS scores, and baseline vitamin D levels. Univariate associations of success with these determinants were tested with Pearson χ² tests with a continuity correction for nominal determinants and with the Student t test for continuous determinants. Determinants (mentioned above) with P values less than .10 were tested in a stepwise (backward Wald) multivariate logistic regression model with success as the dependent variable.

To compare the effects of a single dose vs repeated doses of vitamin D, we tested the difference between the vitamin D–placebo group and the vitamin D–vitamin D group in terms of the self-reported change in pain at 12 weeks and the change in ability to climb stairs (on 5-point Likert scales) with the Pearson χ² test for trend.

**Possible Delayed Effect of Vitamin D Supplementation**

To explore a possible delayed effect of vitamin D supplementation, we compared pain improvement at 12 weeks among the 3 groups by means of the Kruskall-Wallis test. When the result was significant, we conducted a pairwise comparison with a Pearson χ² test for trend using a Bonferroni correction.
RESULTS
A total of 88 patients were screened for eligibility, of whom 84 (95%) were enrolled (Figure 1). Fifteen patients did not complete the full protocol because they did not attend the second interview (5 patients) or third interview (10 patients). Analysis of outcomes at 6 weeks were based on 79 patients.

Baseline demographic and laboratory characteristics were balanced between the groups, as was season of enrollment (Table 2). Overall, 77.4% of patients

---

Figure 1. Patient enrollment, randomization, and disposition.

---

- **88 Patients assessed for eligibility**
  - 4 Excluded
    - 3 Did not meet inclusion criteria
    - 1 Had other reason

- **44 Allocated to vitamin D** (Vitamin D$_3$ 15,000 IU)
  - 1 Lost to follow-up
    - 1 Data lost
  - 43 First analysis
    - 2 Stopped before second randomization
    - 2 No show
  - 41 Randomized
    - 24 Allocated to vitamin D (Vitamin D$_3$ 150,000 IU)
      - 1 Lost to follow-up
        - 1 No show
      - 23 Second analysis (22 second 25-OH-D)
    - 17 Allocated to placebo
      - 1 Lost to follow-up
        - 1 No show
      - 16 Second analysis (16 second 25-OH-D)
  - Follow-up
    - 4 Lost to follow-up
      - 1 Data lost
      - 3 No show

- **40 Allocated to placebo**
  - 3 Stopped before second randomization
    - 1 Pregnancy
    - 1 Protocol broken
    - 1 No show
  - 36 First analysis
    - 3 Stopped before second randomization
      - 1 Pregnancy
      - 1 Myocardial infarction
      - 1 No show
  - Analysis
    - 33 Allocated to vitamin D (Vitamin D$_3$ 150,000 IU)
      - 3 Lost to follow-up
        - 1 Pregnancy
        - 1 Myocardial infarction
        - 1 No show
      - 30 Second analysis (29 second 25-OH-D)
  - Follow-up
    - 17 Allocated to placebo
      - 1 Lost to follow-up
        - 1 No show

---

*a These patients were available for 25-OH-D analysis.

25-OH-D = 25-hydroxyvitamin D
were female, and 53.0% had widespread pain, with high VAS scores (mean, 86.1). The mean 25-OH-D level at baseline was 19.7 nmol/L. Initial VAS scores and use of concomitant treatment were lower in the vitamin D–vitamin D group as compared with the other groups; the groups did not differ with respect to other clinical features.

**Primary Outcome: Change in Pain at 6 Weeks**

Primary efficacy analyses showed the vitamin D group was significantly more likely to report their pain was improved at week 6 when compared with the placebo group (34.9% vs 19.5%, \( P = .04 \)) (Table 3). Also noteworthy was a lower rate of worsening of pain in the former group (25.6% vs 44.4%). The 2 groups were similar with respect to use of physiotherapy or pain-relieving medication (data not shown).

**Secondary Outcomes**

Patients in the vitamin D were also markedly more likely than those in the placebo group to have an improvement in self-reported ability to walk stairs at 6 weeks (21.0% vs 8.4%, \( P = .008 \)) (Table 4). Here, too, the vitamin D group was much less likely to have deterioration than the placebo group (23.3% vs 55.5%).

Improvements in VAS scores for pain and for ability to walk stairs with vitamin D did not reach statistical significance.

**Determinants of Treatment Success**

In the entire study population, localization of pain or clinical patterns such as proximal pain or widespread pain were not correlated with improvement at 6 weeks in univariate analysis, except for pain in the legs and disability in climbing stairs (Table 5). In a multivariate analysis, pain in the legs remained the only significant variable in the model: patients having a higher

---

**Table 2. Patient Characteristics at Baseline, Overall and by Subsequent Group**

| Characteristic                           | Total (N = 84) | Week 6 Group | Week 12 Group | Vitamin D–Vitamin D | Vitamin D–Placebo | Placebo–Vitamin D |
|------------------------------------------|---------------|--------------|---------------|---------------------|--------------------|-------------------|
| Age, mean (SD), y                        | 41.9 (10.4)   | 42.9 (9.5)   | 40.8 (11.3)   | 42.9 (10.0)         | 43.8 (9.4)         | 41.2 (11.5)       |
| Sex, female, No. (%)                     | 64 (76.2)     | 37 (84.1)    | 28 (70.0)     | 21 (87.5)           | 13 (76.5)          | 22 (66.7)         |
| Enrolled October-March, No. (%)          | 47 (54.8)     | 28 (63.6)    | 19 (47.5)     | 13 (54.2)           | 13 (76.3)          | 14 (42.4)         |
| 25-OH-D, mean (SD), nmol/L               | 19.7 (9.7)    | 19.7 (10.7)  | 19.7 (8.8)    | 20.2 (10.3)         | 18.9 (12.5)        | 19.6 (9.0)        |
| Physiotherapy in past month, No. (%)     | 15 (17.9)     | 8 (18.2)     | 7 (17.5)      | 2 (8.3)             | 5 (29.4)           | 7 (21.2)          |
| Number of days of pain medication in past week, mean (SD) | 2.8 (2.8) | 2.5 (2.9) | 3.2 (2.8) | 1.5 (2.3) | 3.7 (3.2) | 3.2 (2.8) |

| Pain characteristics†                      |               |              |               |                     |                    |                   |
| Widespread pain, No. (%)                   | 44 (52.4)     | 22 (50.0)    | 22 (55.0)     | 8 (33.3)            | 12 (70.0)          | 19 (57.6)         |
| Proximal pain, No. (%)                     | 5 (6.0)       | 3 (7.0)      | 2 (5.0)       | 3 (12.5)            | 0 (0.0)            | 1 (3.0)           |
| Joint pain, No. (%)                        | 9 (10.7)      | 6 (14.0)     | 3 (7.5)       | 5 (20.8)            | 1 (5.9)            | 1 (3.0)           |
| VAS pain scores§                           |               |              |               |                     |                    |                   |
| Highest, mean (SD)                         | 86.1 (16.9)   | 83.0 (20.6)  | 89.5 (11.0)   | 79.0 (24.9)         | 86.4 (13.1)        | 90.7 (9.9)        |
| Average, mean (SD)                         | 62.7 (19.4)   | 60.6 (21.2)  | 65.1 (17.2)   | 56.4 (24.4)         | 65.2 (16.1)        | 66.0 (17.1)       |
| VAS difficulty climbing stairs, mean (SD)  | 64.6 (29.4)   | 62.5 (31.6)  | 66.9 (26.9)   | 60.1 (30.2)         | 66.6 (35.0)        | 71.2 (24.6)       |

25-OH-D = 25-hydroxyvitamin D; VAS = visual analogue scale.

†See Methods for definitions.

‡Possible scores ranged from 0 to 100, with higher scores indicating worse pain.

§Mean of the highest VAS pain scores per patient at baseline.

**Table 3. Change in Self-Assessed Pain at 6 Weeks, Without and With Imputation**

| Analysis and Group | Much Less Pain No. (%) | Less Pain No. (%) | Equal No. (%) | More Pain No. (%) | Much More Pain No. (%) |
|--------------------|------------------------|-------------------|---------------|-------------------|-----------------------|
| Without imputation |                        |                   |               |                   |                       |
| Vitamin D          | 2 (5.0)                | 13 (32.5)         | 17 (42.5)     | 6 (15.0)          | 2 (5.0)               |
| Placebo            | 1 (2.9)                | 6 (17.1)          | 13 (37.1)     | 7 (20.0)          | 8 (22.9)              |
| With imputation    |                        |                   |               |                   |                       |
| Vitamin D          | 2 (4.7)                | 13 (30.2)         | 17 (39.5)     | 7 (16.3)          | 4 (9.3)               |
| Placebo            | 1 (2.8)                | 6 (16.7)          | 13 (36.1)     | 7 (19.4)          | 9 (25.0)              |

Notes: Linear-by-linear association without imputation: \( P = .01 \). Linear-by-linear association with imputation: \( P = .04 \).
Vitamin D for Nonspecific Musculoskeletal Pain

VAS score for pain in the legs at baseline had significantly lower odds of an improvement in pain (odds ratio = 0.20; 95% confidence interval, 0.06-0.68). We found no association between 25-OH-D levels at baseline and improvement at week 6.

Possible Delayed Effect of Supplementation
Changes in pain differed significantly among the 3 groups ($P = .006$). Pairwise comparisons revealed that only the difference between vitamin D–vitamin D group and the placebo–vitamin D group was significant ($P = .005$), with a larger proportion of patients in the former group having an improvement of pain (Table 6). Differences between week 6 and week 12 were not significant.

Adverse Effects
We did not find any adverse effects of vitamin D supplementation during or after the trial.

DISCUSSION
We found an improvement in self-assessed pain 6 weeks after administration of 150,000 IU vitamin D$_3$ in non-Western immigrants having vitamin D deficiency. Improvement was also seen in the ability to walk stairs, and there was a weak trend toward greater benefit after 12 weeks vs 6 weeks of supplementation. Having less vs more pain in the legs was associated with better odds of improvement in both pain and stair-walking ability. In contrast to the findings for self-assessed change in pain on Likert scales, VAS scores for pain did not improve significantly after supplementation with vitamin D.

Our results are in line with several case reports but not with the results of 2 trials conducted in the United States. These trials included mainly white patients having long-standing pain with a

Table 4. Change in Self-Assessed Ability to Walk Stairs at 6 Weeks, Without and With Imputation

| Analysis and Condition | Much Better No. (%) | Better No. (%) | Equal No. (%) | Worse No. (%) | Much Worse No. (%) |
|------------------------|---------------------|----------------|---------------|--------------|-------------------|
| Without imputation     |                     |                |               |              |                   |
| Vitamin D              | 2 (5.1)             | 5 (12.8)       | 24 (61.5)     | 6 (15.4)     | 2 (5.1)           |
| Placebo                | 0 (0)               | 2 (5.7)        | 13 (37.1)     | 16 (45.7)    | 4 (11.4)          |
| With imputation        |                     |                |               |              |                   |
| Vitamin D              | 3 (7.0)             | 6 (14.0)       | 24 (55.8)     | 8 (18.6)     | 2 (4.7)           |
| Placebo                | 1 (2.8)             | 2 (5.6)        | 13 (36.1)     | 16 (44.4)    | 4 (11.1)          |

Notes: Linear-by-linear association without imputation: $P = .003$. Linear-by-linear association with imputation: $P = .008$.

Table 5. Determinants of Treatment Success in the Total Study Population

| Determinant | Treatment Success, n/N (%) | $P$ Value |
|-------------|----------------------------|-----------|
| Age, y      |                           | .74       |
| <45         | 9/40 (22.5)                |           |
| ≥45         | 10/35 (28.6)               |           |
| Sex         |                           | .20       |
| Female      | 17/57 (29.8)               |           |
| Male        | 2/18 (11.1)                |           |
| Enrolled    |                           | .32       |
| October-March | 13/42 (31.0) |           |
| April-September | 6/33 (18.2) |           |
| Joint pain  |                           | .34       |
| No          | 16/69 (23.2)               |           |
| Yes         | 3/6 (50.0)                 |           |
| Proximal pain|                        | .80       |
| No          | 17/70 (24.3)               |           |
| Yes         | 2/5 (40.0)                 |           |
| Widespread pain|                      | .94       |
| No          | 9/33 (27.3)                |           |
| Yes         | 10/42 (23.8)               |           |

| Determinant | Treatment Success, n/N (%) | $P$ Value |
|-------------|----------------------------|-----------|
| VAS pain arms|                         | .19       |
| ≤Median     | 13/39 (33.3)              |           |
| >Median     | 6/35 (17.1)               |           |
| VAS pain neck/shoulders |          | .14       |
| ≤Median     | 13/38 (34.2)              |           |
| >Median     | 6/36 (16.7)               |           |
| VAS pain legs|                        | .01       |
| ≤Median     | 15/38 (39.5)              |           |
| >Median     | 4/35 (11.4)               |           |
| VAS pain back|                        | .29       |
| ≤Median     | 12/37 (32.4)              |           |
| >Median     | 7/37 (18.9)               |           |
| VAS disability climbing stairs |      | .01       |
| ≤Median     | 14/36 (38.9)              |           |
| >Median     | 4/36 (11.1)               |           |
| Baseline 25-OH-D |                  | 1.00      |
| <25 nmol/L | 13/54 (24.1)              |           |
| ≥25 nmol/L | 4/16 (25.0)               |           |

Notes: Treatment success was defined as any improvement in pain 6 weeks after treatment. Stepwise logistic regression analysis with the 2 significant determinants in univariate analysis showed that the VAS score for pain in the legs was the only significant ($P = .01$) predictor of success (odds ratio = 0.20; 95% confidence interval, 0.06-0.68), whereby patients having a higher VAS score for pain in the legs at baseline had less improvement in pain 6 weeks after vitamin D supplementation.
mean 25-OH-D level of 45 nmol/L. The first trial compared 13 treatments of 50,000 IU vitamin D3 in 3 months vs placebo in 42 patients and found no differences in VAS pain scores.14 One-half of the placebo group had normalization of their 25-OH-D levels by exposure to sunshine. The second trial found no improvement in several pain scores after 8 weeks of 50,000 IU vitamin D3 weekly.15 The authors mention the short duration of the trial as a possible reason for this negative result. Nevertheless, there was a significant improvement in ability to walk stairs in their treatment group.

What could explain the differences between these findings and ours? First, in our trial, designed for optimal applicability in clinical practice, we chose to assess self-assessed change in pain as a measure close to physicians’ typical way of evaluating pain treatment. This verbal score is used before and is probably more reliable than the VAS scores.29,36–38 Second, the difference in population (white vs non-Western) and 25-OH-D levels at baseline (45 nmol/L vs 20 nmol/L) between our study and the study of Warner et al,34 and the spontaneous improvement of 25-OH-D levels in that small study, might explain the lack of an effect.39 Third, the vitamin D3 used in that study might have had less effect than the vitamin D3 we used.40–43

Another RCT assessing the effect of vitamin D supplementation on pain was published recently.16 This trial among elderly Turkish patients (with or without vitamin D deficiency) from a rheumatology outpatient clinic found improvement in pain 4 weeks after administration of a megadose of vitamin D. Regrettably, the authors do not report on the statistical significance of the difference in change between the vitamin D and placebo groups.

Secondary Outcomes

In our population, we found a statistically significant self-assessed improvement in ability to walk stairs 6 weeks after receipt of vitamin D, which likely reflects enhanced strength. Interventional studies showing that vitamin D supplementation has a positive effect on strength have focused mainly on the legs, as have most case reports.

We did not find any improvement in VAS scores for pain. This lack of improvement might reflect greater validity of the verbal Likert scales than the abstract VAS scores in our probably less educated population.

Determinants of Treatment Success

In our population, patients with a higher VAS score for pain in the legs at baseline had less improvement in pain 6 weeks after vitamin D supplementation. It has long been known that osteomalacia can produce pain in the legs,12 but studies have since found vitamin D deficiency to be associated with pain in a variety of other locations. Most of these studies have related vitamin D deficiency with widespread pain and fibromyalgia, but back pain and also headache have been described as leading symptoms too.29,44,45

In our study, these different pain locations did not correlate with improvement on supplementation. Neither did, as expected, pain in the joints. But given the relatively small number of patients, it may have been somewhat problematic to include a large number of important variables in the multivariate model.

Dose and Duration of Supplementation

A supplementation dose of 100,000 IU vitamin D3 is enough to keep 25-OH-D levels above 82 nmol/L for 6 weeks in most patients who start with a level of 60 nmol/L.46 Six weeks after having received 150,000 IU, our population starting with a mean 25-OH-D level of 20 nmol/L had reached a mean level of just 63.5 nmol/L, however, at 12 weeks, the value was even lower, at less than 40 nmol/L. The supplementation dose used thus may have been too low to achieve the full desired impact. The greater improvement at 12 weeks in the vitamin D–vitamin D group compared with the placebo–vitamin D group supports this hypothesis.

Limitations

Some limitations of our study are due to the type of intervention. First, a single megadose of vitamin D enabled maximal patient compliance, but the duration of treatment might have been too short (as noted above).

Second, the heterogeneity of the enrolled patients may have played a role. We chose inclusion and exclusion criteria to maximize applicability in general practice; specific reasons for the pain were not ascertained.
Nevertheless, only 3 patients had to be excluded after enrollment because their pain was found to be due to a specific condition, and in the remaining patients, physicians did not mention any specific relevant disease 6 or more months after inclusion. Depression, somatization, and other psychological causes of pain are probably not affected by vitamin D, but are likely prevalent in patients with chronic musculoskeletal pain as well as in vitamin D deficiency. Because we did not measure psychological conditions, we can only speculate that more selective inclusion criteria would have shown a greater effect of supplementation.

A third limitation is lack of data concerning parathyroid hormone (PTH). This hormone, which increases with low 25-OH-D levels, has direct negative effects on skeletal muscles; therefore, one can argue that vitamin D supplementation is only an indirect approach to improving muscle function. Because correlation between PTH and 25-OH-D levels is rather weak, and in most patients, supplementing vitamin D is the safest way to lower PTH levels, we believe omission of PTH testing is unimportant for clinical practice.

Last, in the multivariate model, our power to assess multiple determinants was limited given the study size.

Possible Mechanisms

There are several possible mechanisms to explain why vitamin D supplementation may have a pain-relieving effect: a rapid nongenomic influence of vitamin D on the metabolism of muscle cells, growth of muscle fibers by a slow genomic effect on muscle cells, and a nonspecific effect on the central or peripheral nervous system. As chronic pain is strongly influenced by mood, an antidepressive effect of vitamin D could as well in vitamin D deficiency. Because we did not measure psychological conditions, we can only speculate that more selective inclusion criteria would have shown a greater effect of supplementation.

Trial registration: Title: Vitamin D supplementation and non-specific musculoskeletal disorders. ISRCTN assigned: ISRCTN54027991. Date ISRCTN assigned: June 27, 2007.

References

1. Gloth FM III, Lindsay JM, Zelesnick LB, Greenough WB III. Can vitamin D deficiency produce an unusual pain syndrome? Arch Intern Med. 1991;151(8):1662-1664.

2. Nellen JF, Smulders YM, Jos Friisen PH, Slatts EH, Silberbusch J. Hypovitaminosis D in immigrant women: slow to be diagnosed. BMJ. 1996;312(7030):570-572.

3. Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med. 2000;160(8):1199-1203.

4. Al Faraj S, Al Mutairi K. Vitamin D deficiency and chronic low back pain in Saudi Arabia. Spine (Phila Pa 1976). 2003;28(2):177-179.

5. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, non-specific musculoskeletal pain. Mayo Clin Proc. 2003;78(12):1463-1470.

6. Erkal MZ, Wilde J, Bilgin Y, et al. High prevalence of vitamin D deficiency, secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany: identification of risk factors. Osteoporos Int. 2006;17(8):1133-1140.

7. Mouvis M, Ostor AJK, Crisp AJ, et al. Hypovitaminosis D among rheumatology outpatients in clinical practice. Rheumatology (Oxford). 2008;47(9):1348-1351.

8. Dhesi JK, Jackson SH, Bearne LM, et al. Vitamin D supplementation improves neuromuscular function in older people who fall. Age Ageing. 2004;33(6):589-595.

9. Glerup H, Mikkelsen K, Poulsen L, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int. 2000;66(6):419-424.

10. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged ≥80 y. Am J Clin Nutr. 2004;80(3):752-758.

11. Ward KA, Das G, Berry JL, et al. Vitamin D status and muscle function in post-menarchal adolescent girls. J Clin Endocrinol Metab. 2009;94(2):559-563.

12. Schott GD, Wills MR. Muscle weakness in osteomalacia. Lancet. 1976;1(7660):626-629.

13. de Torrenté de la Jara G, Pécoud A, Favrat B. Musculoskeletal pain in female asylum seekers and hypovitaminosis D. BMJ. 2004;329(7458):156-157.

14. McBeth J, Pye SR, O’Neill TW, et al; EMAS Group. Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study. Ann Rheum Dis. 2010;69(8):1448-1452.

15. Hellwell FS, Ibrahim GH, Karim Z, Sokol K, Johnson H. Unexplained musculoskeletal pain in people of South Asian ethnic group referred to a rheumatology clinic—relationship to biochemical osteomalacia, persistence over time and response to treatment with calcium and vitamin D. Clin Exp Rheumatol. 2006;24(4):424-427.

16. Atherton K, Berry DJ, Parsons T, Macfarlane GJ, Power C. Hypoponen C. Vitamin D and chronic widespread pain in a white middle-aged British population: evidence from a cross-sectional population survey. Ann Rheum Dis. 2009;68(6):817-822.

17. Simpson RJ, Thomas GA, Arnold AJ. Identification of 1,25-dihydroxyvitamin D, receptors and activities in muscle. J Biol Chem. 1985;260(15):8862-8891.

18. Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1,25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochem J. 2001;33(1):19-24.
